American Association for the Study of Liver Diseases 2003 Conference

Conference Reports for NATAP


American Association for the Study of Liver Diseases 2003 Conference Boston, MA Nov 25-29, 2003

	AASLD - Treating HCV with Normal ALT with Pegasys plus Ribavirin - (11/10/03) AASLD - DELAYED RECOVERY OF PEGYLATED INTERFERON AND RIBAVIRIN INDUCED ANEMIA - (11/10/03) AASLD - Albuferon: new HCV drug in early study - (11/10/03) AASLD - Continuous Pump Infusion of Consensus Interferon in Non-respondersto HCV Therapy: pilot study - (11/10/03) Rofecoxib (Vioxx) Prevents Reduction in Platelets During Pegasys Therapy for HCV: short term pilot study - (11/05/03) LdT: new drug for HBV, phase II study results - (11/05/03) Effects of Lamivudine on Disease Progression and Development of Liver Cancer in Advanced Chronic Hepatitis B: a prospective double-blind placebo controlled clinical trial - (11/05/03) HCV Sexual Transmission --MSM & Heterosexual - (11/04/03) Study Urges Doctors to Screen for Hepatitis - (11/04/03) Hepatitis C in Elderly Goes Undetected and Is More Severe - (11/04/03) Long Term (96 Weeks) Adefovir in HBeAg Negative Chronic Hepatitis B Results in Significant Virological, Biochemical, and Histologic Improvement - (11/04/03) LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C PATIENTS - RESPONSE TO THERAPY AND INCIDENCE OF LIVER-RELATED COMPLICATIONS - (11/04/03) Effects of Lamivudine on Disease Progression and Development of Liver Cancer in Advanced Chronic Hepatitis B: a prospective double-blind placebo controlled clinical trial - (11/04/03) High Dose Peginterferon for Non-responders, and Naïve & Relapsers - (10/31/03) PROGRESSION AND TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION IN PATIENTS CO-INFECTED WITH HIV. - (10/30/03) EFFICACY AND TOLERABILITY OF PREEMPTIVE INTERFERON (IFN) VERSUS IFN PLUS RIBAVIRIN (RBV) TREATMENT IN HEPATITIS C VIRUS (HCV) INFECTED LIVER TRANSPLANT RECIPIENTS - (10/30/03) HCV Vaccines: early research - (10/30/03) The Immune Response to HCV: implications for HCV/HIV co-infection - (10/30/03) BILN 2061: HCV protease inhibitor - (10/30/03) SCHERING-PLOUGH REPORTS NOVEL INVESTIGATIONAL PROTEASE INHIBITOR SHOWS IN VITRO ANTIVIRAL ACTIVITY IN HEPATITIS C INFECTION - (10/29/03) Early Viral Kinetics Prediction of Sustained Viral Response After 1 or 4 Weeks of Peg-Interferon-a-2a (40KD) and Ribavirin Therapy (DITTO-HCV Project) - (10/29/03) FIBROSIS PROGRESSION IN 914 HIV-HCV CO-INFECTED PATIENTS IS STRONGLY RELATED WITH AGE: EUROPEAN COLLABORATIVE STUDY - (10/29/03) BENEFIT OF SUSTAINED WEIGHT LOSS AND EXERCISE IN OVERWEIGHT PATIENTS WITH LIVER DISEASE - (10/28/03) Press Release from Vertex Pharmaceuticals - (10/28/03) Hepatitis C: new antiviral developments - (10/28/03) Pegasys plus Ribavirin (Copegus) for African-Americans with Hepatitis C Genotype 1 - (10/27/03) Sexual Transmission of Hepatitis C Virus in Heterosexual Monogomous Couples - The HCV Partners Study - (10/27/03) Pegasys/Ribavirin in African Americans Showed Improved or Stabilized Fibrosis in Nonresponders - (10/27/03) Natural History of Fibrosis in Chronic Hepatitis C - (10/27/03) Intrafamilial Transmission of Hepatitis C Virus in Patients with Acute Hepatitis C: correlation with virologic and immunologic parameters - (10/27/03) COMPARING THE PUBLIC HEALTH BURDEN OF CHRONIC HEPATITIS C AND HIV INFECTION IN UNITED STATES - (10/27/03)